Mo polyoxometalate nanoparticles inhibit tumor growth and vascular endothelial growth factor induced angiogenesis
Source abstract
Abstract
Tumor growth depends on angiogenesis, which can furnish the oxygen and nutrients that proliferate tumor cells. Thus, blocking angiogenesis can be an effective strategy to inhibit tumor growth. In this work, three typical nanoparticles based on polyoxometalates (POMs) have been prepared; we investigated their capability as antitumor and anti-angiogenesis agents. We found that Mo POM nanoparticles, especially complex 3, inhibited the growth of human hepatocellular liver carcinoma cells (HepG2) through cellular reactive oxygen species levels’ elevation and mitochondrial membrane potential damage. Complex 3 also suppressed the proliferation, migration, and tube formation of endothelial cells in vitro and chicken chorioallantoic membrane development ex vivo. Furthermore, western blot analysis of cell signaling molecules indicated that Mo POMs blocked the vascular endothelial growth factor receptor 2-mediated ERK1/2 and AKT signaling pathways in endothelial cells. Using transmission electron microscopy, we demonstrated their cellular uptake and localization within the cytoplasm of HepG2 cells. These results indicate that, owing to the extraordinary physical and chemical properties, Mo POM nanoparticles can significantly inhibit tumor growth and angiogenesis, which makes them potential drug candidates in anticancer and anti-angiogenesis therapies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Polyoxometalates: Synthesis and Applications · Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. 10.1056/NEJM19951228333260810.1056/NEJM199512283332608 ↗
2. 10.1016/S0092-8674(00)80108-710.1016/S0092-8674(00)80108-7 ↗
3. 10.1016/j.ejphar.2011.06.01510.1016/j.ejphar.2011.06.015 ↗
4. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
5. 10.1111/jcmm.2005.9.issue-410.1111/jcmm.2005.9.issue-4 ↗
6. 10.1007/s10456-012-9270-410.1007/s10456-012-9270-4 ↗
7. 10.1182/blood-2007-08-10971010.1182/blood-2007-08-109710 ↗
8. 10.2174/15680090878349712210.2174/156800908783497122 ↗
9. 10.1042/0264-6021:360025510.1042/0264-6021:3600255 ↗
10. 10.1158/0008-5472.CAN-11-340610.1158/0008-5472.CAN-11-3406 ↗
11. 10.1073/pnas.17239829910.1073/pnas.172398299 ↗
12. Mendel D B · Clin. Cancer Res. · 2000 · 6 · 4848
13. 10.1634/theoncologist.9-suppl_1-210.1634/theoncologist.9-suppl_1-2 ↗
14. 10.1161/STROKEAHA.111.64798210.1161/STROKEAHA.111.647982 ↗
15. 10.1038/sj.bjc.660381310.1038/sj.bjc.6603813 ↗
16. 10.1002/smll.v9.2010.1002/smll.v9.20 ↗
17. 10.1016/j.jinorgbio.2004.10.02010.1016/j.jinorgbio.2004.10.020 ↗
18. 10.1039/b504585a10.1039/b504585a ↗
19. 10.1016/j.ejmech.2011.03.03610.1016/j.ejmech.2011.03.036 ↗
20. 10.1002/(ISSN)1521-375710.1002/(ISSN)1521-3757 ↗
21. 10.1016/j.biomaterials.2012.09.03110.1016/j.biomaterials.2012.09.031 ↗
22. 10.1016/j.biomaterials.2013.11.00710.1016/j.biomaterials.2013.11.007 ↗
23. 10.1002/(ISSN)1521-377310.1002/(ISSN)1521-3773 ↗
24. 10.1002/(ISSN)1521-377310.1002/(ISSN)1521-3773 ↗
25. 10.1039/C3NR05906E10.1039/C3NR05906E ↗
26. 10.1084/jem.192.4.57110.1084/jem.192.4.571 ↗
27. 10.1158/0008-5472.CAN-07-078310.1158/0008-5472.CAN-07-0783 ↗
28. 10.1007/978-94-007-2869-110.1007/978-94-007-2869-1 ↗
29. 10.1126/science.109205310.1126/science.1092053 ↗
30. 10.1021/jm100416n10.1021/jm100416n ↗
31. 10.1021/bi050401x10.1021/bi050401x ↗
32. 10.1038/nrc90910.1038/nrc909 ↗
33. 10.1152/ajpheart.00113.200610.1152/ajpheart.00113.2006 ↗
34. 10.1042/BST031117110.1042/BST0311171 ↗
35. Hood J D · Am. J. Physiol. Heart Circ. Physiol. · 1998 · 274 · H105410.1152/ajpheart.1998.274.3.H1054 ↗
36. 10.1161/01.CIR.95.4.103010.1161/01.CIR.95.4.1030 ↗
37. Dong G · Cancer Res. · 2001 · 61 · 5911